Search
for

    Research 3 of 145

    1. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma British Journal of Dermatology · 2012 · 173 citations
    2. The Cutaneous Side Effects of Selective BRAF Inhibitors and Anti-CTLA4 Agents: the Growing Role of the Dermatologist in the Management of Patients with Metastatic Melanoma Current Dermatology Reports · 2013 · 6 citations
    3. Dermatologic Adverse Events from Cancer Treatments Springer eBooks · 2018 · 2 citations
    All research results →

    Learn

    — no results

    Try a deeper search in learn →

    Community

    — no results

    Try a deeper search in community →